Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.chest.2019.09.039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Test-retest reliability of cardiopulmonary exercise test-derived metrics in individuals with COPD versus healthy controls.
Clin Physiol Funct Imaging
January 2025
Centre for Physical Activity Research, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Background: Cardiopulmonary exercise testing (CPET) is usually considered the gold standard for assessing maximal oxygen consumption (V̇O), a health and performance marker in patients with chronic obstructive pulmonary disease (COPD). Despite the widespread application of CPET, the absolute and relative test-retest reliability of CPET-derived metrics remains unexamined.
Objective: To examine and compare test-retest reliability of CPET derived metrics in individuals with COPD and healthy matched controls.
Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
COPD
December 2025
Division of Respirology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Background: Despite limited breakthroughs in COPD pharmacotherapy, recent trials have shown promising results for biologics in COPD patients. However, robust evidence synthesis in this area is currently lacking.
Methods: We conducted a systematic review of MEDLINE, EMBASE, and Cochrane CENTRAL from inception to July 17, 2024, to identify randomized trials of biologic medications in patients with COPD.
The usefulness of Charlson Comorbidity Index (CCI) scoring in predicting all-cause mortality in Outpatients with Clinical Diagnoses of COPD.
J Multimorb Comorb
January 2025
Trinity Health of New England, St. Francis Hospital, Hartford, CT, USA.
Background: Since comorbid conditions are frequently present in chronic obstructive pulmonary disease (COPD) and affect outcome, a composite scoring system to quantify comorbidity might be helpful in assessing mortality risk.
Methods: We tested the hypothesis that the Charlson Comorbidity Index (CCI) score at the time of an outpatient medical clinic encounter for COPD predicts all-cause mortality. Cox Proportional Hazards analyses were used in 200 randomly selected patients to relate CCI scores to all-cause mortality out to 5 years.
Changes of b2-microglobulin and electrolytes in different stages of COPD and their value in evaluating prognosis.
J Med Biochem
November 2024
Central South University, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Department 2 of Respiratory and Critical Medicine, Zhuzhou, China.
Background: To investigate the changes of b2-microglobulin and electrolyte in different stages of chronic obstructive pulmonary disease (COPD) and the value of evaluating prognosis.
Methods: A retrospective study was undertaken on 120 patients diagnosed with COPD and treated at our respiratory department between February 1, 2020, and January 31, 2023. These patients were classified into three groups based on the GOLD classification: mild (FEV1 > 81%), moderate (51% < FEV1 ≤ 80%), and severe (FEV1 ≤ 50%).
Managing cognitive impairment in patients with chronic obstructive pulmonary disease (COPD) in Saudi Arabia: what are the current practices?
Ann Med
December 2025
Adult Critical Care Department, King Abdulaziz University Hospital-Jeddah, Jeddah, Saudi Arabia.
Objective: Cognitive impairment is a common comorbidity, yet overlooked, in patients with chronic obstructive pulmonary disease (COPD). However, little is known about the current practice and perceptions of physicians on recognising and managing cognitive impairment in patients with COPD in Saudi Arabia. This study aimed to investigate current practices and perceptions of physicians in Saudi Arabia regarding the recognition and management of cognitive impairment in COPD patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!